<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> is a risk factor for progression of non-alcoholic <z:hpo ids='HP_0001397'>fatty liver</z:hpo> disease (NAFLD) to <z:mp ids='MP_0003045'>fibrosis</z:mp> and <z:hpo ids='HP_0001394'>cirrhosis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We examined the prevalence of advanced <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">liver disease</z:e> in people with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and analysed the effectiveness of liver function tests (LFTs) as a screening tool </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Participants (n = 939, aged 61-76 years) from the Edinburgh Type 2 <z:mp ids='MP_0002055'>Diabetes</z:mp> Study, a randomly selected population of people with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, underwent abdominal ultrasonography </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="1" ids="16336">Hyaluronic acid</z:chebi> (HA) and platelet count/spleen diameter ratio (PSR) were used as non-invasive markers of <z:hpo ids='HP_0001395'>hepatic fibrosis</z:hpo> and <z:hpo ids='HP_0001409'>portal hypertension</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Subjects were screened for secondary causes of <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">liver disease</z:e> that excluded them from a diagnosis of NAFLD </plain></SENT>
<SENT sid="5" pm="."><plain>The efficacy of LFTs [alanine aminotransferase (ALT) and gamma-glutamyltransferase (GGT)] in screening for <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">liver disease</z:e> was determined </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: <z:hpo ids='HP_0001394'>Cirrhosis</z:hpo> was identified by ultrasound in four participants (0.4%) </plain></SENT>
<SENT sid="7" pm="."><plain>Ten (1.1%) had evidence of <z:hpo ids='HP_0001409'>portal hypertension</z:hpo> (PSR &lt; 909), and two (0.2%) had <z:hpo ids='HP_0001402'>hepatocellular carcinoma</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Fifty-three participants (5.7%) had evidence of <z:hpo ids='HP_0001395'>hepatic fibrosis</z:hpo> (HA &gt; 100 ng/ml in the absence of <z:e sem="disease" ids="C0022408" disease_type="Disease or Syndrome" abbrv="">joint disease</z:e>); a further 169 had HA &gt; 50 ng/ml </plain></SENT>
<SENT sid="9" pm="."><plain>In participants with NAFLD-related <z:mp ids='MP_0003045'>fibrosis</z:mp> (HA &gt; 100 ng/ml), 12.5% had an <z:mp ids='MP_0002941'>elevated ALT level</z:mp> and 17.5% had an elevated GGT level </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: The prevalence of <z:hpo ids='HP_0001395'>hepatic fibrosis</z:hpo> and <z:hpo ids='HP_0001394'>cirrhosis</z:hpo> were lower than expected </plain></SENT>
<SENT sid="11" pm="."><plain>The use of LFTs to screen for <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">liver disease</z:e> missed most cases of <z:mp ids='MP_0003045'>fibrosis</z:mp> predicted by raised HA levels </plain></SENT>
</text></document>